Pierre Gravier - 02 Jan 2026 Form 4 Insider Report for PTC THERAPEUTICS, INC. (PTCT)

Role
CHIEF FINANCIAL OFFICER
Signature
/s/ Avraham S. Adler, Attorney-in-Fact
Issuer symbol
PTCT
Transactions as of
02 Jan 2026
Net transactions value
$0
Form type
4
Filing time
06 Jan 2026, 17:20:09 UTC
Previous filing
17 Jul 2025
Next filing
08 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Gravier Pierre CHIEF FINANCIAL OFFICER C/O PTC THERAPEUTICS, INC., 500 WARREN CORPORATE CENTER DRIVE, WARREN /s/ Avraham S. Adler, Attorney-in-Fact 06 Jan 2026 0001984065

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PTCT Common Stock Award $0 +20,000 +28% $0.000000 92,449 02 Jan 2026 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PTCT Stock Option (Right to Buy) Award $0 +50,000 $0.000000 50,000 02 Jan 2026 Common Stock 50,000 $76.74 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units granted on January 2, 2026 that vest in four equal installments over four years, commencing on January 2, 2027.
F2 Includes 272 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended June 30, 2025, and 257 shares of common stock acquired under the Issuer's employee stock purchase plan for the period ended December 31, 2025.
F3 This option was granted on January 2, 2026, and vests over four years, with 25% of the shares underlying the option vesting on January 2, 2027, and an additional 6.25% of the original number of shares underlying the option vesting at the end of each successive three-month period thereafter, beginning on April 2, 2027.